Discover a study where findings revealed that total radiographic disappearance of metastases occurred in 15% of patients.

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that it has selected Cardinal Health ...

Following recent U.S. Food and Drug Administration (FDA) approval 2, and in preparation for commercial launch in H1 2025, Telix has contracted with Cardinal Health to enable availability across a wide ...

Rashes are a common side effect of some prostate cancer treatments. Rarely, they may be caused by cancer cells.

The fact that USA Fencing maintains policies allowing biological males who identify as female to compete against women is indefensible.

Elevated circulating tumor DNA (ctDNA) fraction and tumor suppressor gene loss are associated with worse prognosis in patients with prostate cancer liver metastases (PCLM), accord ...

Guidelines created by a multi-disciplinary panel of specialists focus on implementation of novel treatments and technologies for which level 1 evidence is lacking.

A new FDA approval has brought a renewed sense of hope as an innovative new treatment approach is now available to ...

More women than men are prone to hormonal acne and it is affected by the monthly menstrual cycle, pregnancy and childbirth, ...

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

The radiopharmaceutical lutetium 177 can be used after radium 223 to treat metastatic castration-resistant prostate cancer.

SARMs can lower natural testosterone levels, so a recovery phase may be needed after the cycle. For LGD-4033, the effect on ...